Abeona Therapeutics (ABEO) Competitors $5.64 -0.04 (-0.70%) Closing price 04:00 PM EasternExtended Trading$5.75 +0.11 (+2.02%) As of 05:14 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock ABEO vs. SDGR, HROW, AMPH, NUVB, WVE, ETNB, TLRY, PGEN, RCUS, and NTLAShould you be buying Abeona Therapeutics stock or one of its competitors? The main competitors of Abeona Therapeutics include Schrodinger (SDGR), Harrow (HROW), Amphastar Pharmaceuticals (AMPH), Nuvation Bio (NUVB), WAVE Life Sciences (WVE), 89BIO (ETNB), Tilray Brands (TLRY), Precigen (PGEN), Arcus Biosciences (RCUS), and Intellia Therapeutics (NTLA). These companies are all part of the "pharmaceutical products" industry. Abeona Therapeutics vs. Its Competitors Schrodinger Harrow Amphastar Pharmaceuticals Nuvation Bio WAVE Life Sciences 89BIO Tilray Brands Precigen Arcus Biosciences Intellia Therapeutics Schrodinger (NASDAQ:SDGR) and Abeona Therapeutics (NASDAQ:ABEO) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their earnings, profitability, dividends, risk, valuation, analyst recommendations, media sentiment and institutional ownership. Which has more volatility & risk, SDGR or ABEO? Schrodinger has a beta of 1.79, indicating that its stock price is 79% more volatile than the S&P 500. Comparatively, Abeona Therapeutics has a beta of 1.67, indicating that its stock price is 67% more volatile than the S&P 500. Does the media refer more to SDGR or ABEO? In the previous week, Schrodinger had 6 more articles in the media than Abeona Therapeutics. MarketBeat recorded 6 mentions for Schrodinger and 0 mentions for Abeona Therapeutics. Abeona Therapeutics' average media sentiment score of 1.61 beat Schrodinger's score of 1.22 indicating that Abeona Therapeutics is being referred to more favorably in the news media. Company Overall Sentiment Schrodinger Positive Abeona Therapeutics Very Positive Do institutionals and insiders believe in SDGR or ABEO? 79.1% of Schrodinger shares are held by institutional investors. Comparatively, 80.6% of Abeona Therapeutics shares are held by institutional investors. 21.0% of Schrodinger shares are held by insiders. Comparatively, 5.4% of Abeona Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term. Do analysts prefer SDGR or ABEO? Schrodinger presently has a consensus target price of $27.83, indicating a potential upside of 46.26%. Abeona Therapeutics has a consensus target price of $19.50, indicating a potential upside of 245.74%. Given Abeona Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Abeona Therapeutics is more favorable than Schrodinger.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Schrodinger 0 Sell rating(s) 2 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.67Abeona Therapeutics 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has higher earnings & valuation, SDGR or ABEO? Abeona Therapeutics has lower revenue, but higher earnings than Schrodinger. Schrodinger is trading at a lower price-to-earnings ratio than Abeona Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSchrodinger$207.54M6.75-$187.12M-$2.48-7.67Abeona Therapeutics$3.50M82.63-$63.73M$0.708.06 Is SDGR or ABEO more profitable? Abeona Therapeutics has a net margin of 0.00% compared to Schrodinger's net margin of -76.22%. Abeona Therapeutics' return on equity of 89.05% beat Schrodinger's return on equity.Company Net Margins Return on Equity Return on Assets Schrodinger-76.22% -45.70% -24.81% Abeona Therapeutics N/A 89.05%45.64% SummaryAbeona Therapeutics beats Schrodinger on 12 of the 16 factors compared between the two stocks. Get Abeona Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ABEO and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ABEO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ABEO vs. The Competition Export to ExcelMetricAbeona TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$289.22M$3.13B$5.73B$10.28BDividend YieldN/A2.36%5.88%4.63%P/E Ratio8.0621.1776.6726.53Price / Sales82.63450.47525.87121.13Price / CashN/A45.4037.2060.52Price / Book5.589.5613.946.31Net Income-$63.73M-$53.02M$3.29B$271.37M7 Day Performance-13.63%0.38%0.64%2.11%1 Month Performance-20.90%3.93%4.32%6.67%1 Year Performance3.30%8.60%84.14%27.85% Abeona Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ABEOAbeona Therapeutics4.121 of 5 stars$5.64-0.7%$19.50+245.7%+6.6%$289.22M$3.50M8.0690Positive NewsSDGRSchrodinger3.5458 of 5 stars$19.44+1.6%$27.83+43.2%-3.8%$1.41B$207.54M-7.84790Positive NewsHROWHarrow2.9848 of 5 stars$39.77+7.5%$64.67+62.6%-2.5%$1.37B$199.61M-159.08180AMPHAmphastar Pharmaceuticals3.929 of 5 stars$29.26-0.5%$31.60+8.0%-44.2%$1.37B$731.97M10.962,028Positive NewsNUVBNuvation Bio2.7045 of 5 stars$3.48-10.9%$7.50+115.8%+6.5%$1.33B$7.87M-5.5260Positive NewsHigh Trading VolumeWVEWAVE Life Sciences4.4078 of 5 stars$7.58-8.6%$20.33+168.2%+14.0%$1.32B$108.30M-8.42240ETNB89BIO2.6311 of 5 stars$8.57-3.4%$28.00+226.7%-2.9%$1.32BN/A-2.3740Positive NewsTLRYTilray Brands2.8683 of 5 stars$1.12-5.9%$1.94+73.0%-32.2%$1.31B$821.31M-0.482,842Trending NewsPGENPrecigen4.5614 of 5 stars$4.16-4.6%$8.25+98.3%+289.1%$1.30B$4.34M-9.90190Positive NewsRCUSArcus Biosciences1.9009 of 5 stars$11.43-6.3%$21.14+85.0%-30.5%$1.30B$258M-3.60500Positive NewsNTLAIntellia Therapeutics4.4028 of 5 stars$11.84-1.8%$29.05+145.4%-43.0%$1.29B$57.88M-2.52600Gap Up Related Companies and Tools Related Companies Schrodinger Alternatives Harrow Alternatives Amphastar Pharmaceuticals Alternatives Nuvation Bio Alternatives WAVE Life Sciences Alternatives 89BIO Alternatives Tilray Brands Alternatives Precigen Alternatives Arcus Biosciences Alternatives Intellia Therapeutics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ABEO) was last updated on 9/17/2025 by MarketBeat.com Staff From Our PartnersHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredStrange crypto pattern discovered by 40-person research teamSomething unusual is happening inside a 40-person crypto research firm. They're helping 8,000+ ordinary peo...Crypto Swap Profits | SponsoredWhy Trump’s “Smart Dollar” could rewrite the rulesMUST SEE: Donald Trump's Radical Overhaul of the U.S. Dollar Congress just approved President Trump's lates...Stansberry Research | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredForget AI Stocks — This Device Will REPLACE the MicrochipWhile everyone's chasing the same AI plays, George Gilder is focused on something completely different. He ...Banyan Hill Publishing | SponsoredIRS Wants Another Check on Sept 15th—What If You Could Keep It Instead?On September 15th, the IRS collects another round of quarterly tax payments—targeting self-employed profession...American Alternative | SponsoredForget NVDA. Put $1,000 into this stock nowA massive money shift is underway in the AI market. And it's opening up an extraordinary opportunity in a NEW ...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Abeona Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Abeona Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ABEO Stock Alerts